6results about "Integrin superfamily" patented technology

The present invention provides methods for preselecting TILs based on PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3, and / or TIGIT expression, as well as methods for expanding those preselected PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3, and / or TIGIT positive TILs to produce therapeutic TIL populations with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).

A composition is provided comprising a first polypeptide comprising a first fragment or analog or derivative of the extracellular domain of ITGA2B or ITGB3 and a dimerization domain, and a second polypeptide comprising a second fragment or analog or derivative of the extracellular domain of ITGA2B or ITGB3 and a dimerization domain. Polypeptides comprising fragments of the extracellular domain of ITGA2B or ITGB3 are also provided. Pharmaceutical compositions comprising the composition, polypeptide, nucleic acid system, and molecule encoding the polypeptide of the above composition are also provided, as well as therapeutic methods using the above composition or polypeptide, methods for determining suitability for therapeutic use of the above composition or polypeptide, and methods for producing the above composition or protein.

To provide pharmaceutical compositions for the diagnosis, prevention, and / or treatment of age-related cognitive decline, including pathological neurodegeneration. [Solution] A pharmaceutical composition comprising the following components: a therapeutically effective amount of one or more of the following: a CD103 inhibitor, a perforin 1 inhibitor, and an IFNγ inhibitor, wherein the CD103 inhibitor is an anti-CD103 antibody, selected from the group consisting of PE anti-human CD103 antibody derived from clone Ber-ACT8, mouse anti-human CD103 monoclonal antibody (mAb) derived from clone 2G5.1, humanized antibody of 2G5.1, OX-62, humanized antibody of OX-62, anti-mouse CD103 mAb derived from clone 2E7, humanized antibody of 2E7, and paxilin; the perforin 1 inhibitor is selected from the group consisting of diarylthiophene and GSK2126458; and the IFNγ inhibitor is selected from the group consisting of mesopram and locagramide.

The present invention relates to biologics that inhibit angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activation pathway and one other angiogenic factor activation pathway, as well as pharmaceutical compositions of such fusion proteins and methods of making and using the same.

A non-toxic anti-angiogenesis protein that inhibits tumor growth and exhibits in vitro activity in induction of angiogenic endothelial cell apoptosis without targeting VEGF / VEGFR or any other RTK pathways is described. The protein targets integrins αvβ3, at a groove in the βA domain of β3 formed by α2 helix, B-C loop, and α2-α3 loop.